{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:06:47Z","timestamp":1793815607520,"version":"4.6.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["FWOTM780"],"award-info":[{"award-number":["FWOTM780"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["FWOTM869"],"award-info":[{"award-number":["FWOTM869"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G023020N"],"award-info":[{"award-number":["G023020N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008222","name":"Universit\u00e9 de Montpellier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["DEQ20160334919"],"award-info":[{"award-number":["DEQ20160334919"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Montpellier CNRS INSERM iSITE MUSE"},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["DOPAFEAR"],"award-info":[{"award-number":["DOPAFEAR"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41386-022-01324-2","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T17:05:03Z","timestamp":1650560703000},"page":"1304-1314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice"],"prefix":"10.1038","volume":"47","author":[{"given":"B\u0142a\u017cej D.","family":"P\u0119dzich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Sekssaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries","family":"Van Schuerbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-7274","authenticated-orcid":false,"given":"Philippe","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Bockaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1034-606X","authenticated-orcid":false,"given":"Emmanuel","family":"Valjent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7385-681X","authenticated-orcid":false,"given":"Carine","family":"B\u00e9camel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"De Bundel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"1324_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1590\/S2317-17822013000200017","volume":"25","author":"DE Battle","year":"2013","unstructured":"Battle DE. Diagnostic and statistical manual of mental disorders (DSM). Codas. 2013;25:191\u20132.","journal-title":"Codas."},{"key":"1324_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1056\/NEJMra1612499","volume":"376","author":"A Shalev","year":"2017","unstructured":"Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. N Engl J Med. 2017;376:2459\u201369.","journal-title":"N Engl J Med."},{"key":"1324_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/jama.2015.8370","volume":"314","author":"M Maria","year":"2015","unstructured":"Maria M, Steenkamp P. Psychotherapy for military-Related PTSD: a review of randomized clinical trials. JAMA. 2015;314:489\u2013500.","journal-title":"JAMA."},{"key":"1324_CR4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/da.22511","volume":"33","author":"DJ Lee","year":"2016","unstructured":"Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016;33:792\u2013806.","journal-title":"Depress Anxiety."},{"key":"1324_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1192\/bjp.bp.114.148551","volume":"206","author":"M Hoskins","year":"2015","unstructured":"Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, et al. Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. Br J Psychiatry. 2015;206:93\u2013100.","journal-title":"Br J Psychiatry."},{"key":"1324_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.ajp.162.2.214","volume":"162","author":"R Bradley","year":"2005","unstructured":"Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005;162:214\u201327.","journal-title":"Am J Psychiatry"},{"key":"1324_CR7","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1017\/S003329171700349X","volume":"48","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J, et al. Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2018;48:1975\u201384.","journal-title":"Psychol Med."},{"key":"1324_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev.psych.121208.131631","volume":"63","author":"MR Milad","year":"2012","unstructured":"Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience: ten years of progress. Annu Rev Psychol. 2012;63:129.","journal-title":"Annu Rev Psychol."},{"key":"1324_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2014.12.004","volume":"149","author":"N Singewald","year":"2015","unstructured":"Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharm Ther. 2015;149:150\u201390.","journal-title":"Pharm Ther."},{"key":"1324_CR10","doi-asserted-by":"publisher","first-page":"107402","DOI":"10.1016\/j.pharmthera.2019.107402","volume":"204","author":"SB Sartori","year":"2019","unstructured":"Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharm Ther. 2019;204:107402.","journal-title":"Pharm Ther."},{"key":"1324_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S2215-0366(14)00120-5","volume":"2","author":"B Sessa","year":"2015","unstructured":"Sessa B. Turn on and tune in to evidence-based psychedelic research. Lancet Psychiatry. 2015;2:10\u20132.","journal-title":"Lancet Psychiatry."},{"key":"1324_CR12","first-page":"481","volume":"3","author":"MC Mithoefer","year":"2016","unstructured":"Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet. Psychiatry. 2016;3:481\u20138.","journal-title":"Psychiatry."},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","volume":"38","author":"EJ Kyzar","year":"2017","unstructured":"Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. Psychedelic drugs in biomedicine. Trends Pharm Sci. 2017;38:992\u20131005.","journal-title":"Trends Pharm Sci."},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177:391\u2013410.","journal-title":"Am J Psychiatry."},{"key":"1324_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","volume":"23","author":"E Krediet","year":"2020","unstructured":"Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23:385\u2013400.","journal-title":"Int J Neuropsychopharmacol."},{"key":"1324_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3389\/fpsyt.2019.00650","volume":"10","author":"AA Feduccia","year":"2019","unstructured":"Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019;10:650.","journal-title":"Front Psychiatry"},{"key":"1324_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333.","journal-title":"Nat Med"},{"key":"1324_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","volume":"22","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000;22:513\u201321.","journal-title":"Neuropsychopharmacology."},{"key":"1324_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","volume":"5","author":"MC Mithoefer","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5:486\u201397.","journal-title":"Lancet Psychiatry."},{"key":"1324_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","volume":"84","author":"AA Feduccia","year":"2018","unstructured":"Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;84:221\u20138.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"1324_CR21","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1038\/tp.2015.138","volume":"5","author":"MB Young","year":"2015","unstructured":"Young MB, Andero R, Ressler KJ, Howell LL. 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry. 2015;5:e634.","journal-title":"Transl Psychiatry"},{"key":"1324_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neuropharm.2017.10.003","volume":"128","author":"DW Curry","year":"2018","unstructured":"Curry DW, Young MB, Tran AN, Daoud GE, Howell LL. Separating the agony from ecstasy: R(\u2212)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice. Neuropharmacology. 2018;128:196\u2013206.","journal-title":"Neuropharmacology."},{"key":"1324_CR23","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1007\/s00213-017-4684-8","volume":"234","author":"MB Young","year":"2017","unstructured":"Young MB, Norrholm SD, Khoury LM, Jovanovic T, Rauch SAM, Reiff CM, et al. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology. 2017;234:2883\u201395.","journal-title":"Psychopharmacology."},{"key":"1324_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.physbeh.2018.12.007","volume":"199","author":"HS Hake","year":"2019","unstructured":"Hake HS, Davis JKP, Wood RR, Tanner MK, Loetz EC, Sanchez A, et al. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiol Behav. 2019;199:343\u201350.","journal-title":"Physiol Behav."},{"key":"1324_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F, Vizeli P, M\u00fcller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45:462\u201371.","journal-title":"Neuropsychopharmacology."},{"key":"1324_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2210-6-6","volume":"6","author":"DD Han","year":"2006","unstructured":"Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006;6:6.","journal-title":"BMC Pharmacol."},{"key":"1324_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/0269881107083639","volume":"22","author":"CD Verrico","year":"2008","unstructured":"Verrico CD, Lynch L, Fahey MA, Fryer A-K, Miller GM, Madras BK. MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine\/norepinephrine transport inhibitor. J Psychopharmacol. 2008;22:187\u2013202.","journal-title":"J Psychopharmacol"},{"key":"1324_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.biopsych.2006.11.005","volume":"62","author":"JM Trigo","year":"2007","unstructured":"Trigo JM, Renoir T, Lanfumey L, Hamon M, Lesch K-P, Robledo P, et al. 3,4-Methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol Psychiatry. 2007;62:669\u201379.","journal-title":"Biol Psychiatry."},{"key":"1324_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/157015911795017254","volume":"9","author":"Y Hagino","year":"2011","unstructured":"Hagino Y, Takamatsu Y, Yamamoto H, Iwamura T, Murphy DL, Uhl GR, et al. Effects of MDMA on extracellular dopamine and serotonin levels in mice lacking dopamine and\/or serotonin transporters. Curr Neuropharmacol. 2011;9:91\u20135.","journal-title":"Curr Neuropharmacol"},{"key":"1324_CR30","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1111\/bph.13128","volume":"172","author":"A Rickli","year":"2015","unstructured":"Rickli A, Kopf S, Hoener MC, Liechti ME. Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol. 2015;172:3412\u201325.","journal-title":"Br J Pharmacol."},{"key":"1324_CR31","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1523\/JNEUROSCI.5723-07.2008","volume":"28","author":"S Doly","year":"2008","unstructured":"Doly S, Valjent E, Setola V, Callebert J, Herv\u00e9 D, Launay J-M, et al. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci 2008;28:2933\u201340.","journal-title":"J Neurosci"},{"key":"1324_CR32","doi-asserted-by":"publisher","first-page":"e40187","DOI":"10.1371\/journal.pone.0040187","volume":"7","author":"JHP van Wel","year":"2012","unstructured":"van Wel JHP, Kuypers KPC, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG. Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS One. 2012;7:e40187.","journal-title":"PLoS One."},{"key":"1324_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00213-017-4699-1","volume":"235","author":"KPC Kuypers","year":"2018","unstructured":"Kuypers KPC, de la Torre R, Farre M, Pizarro N, Xicota L, Ramaekers JG. MDMA-induced indifference to negative sounds is mediated by the 5-HT 2A receptor. Psychopharmacology. 2018;235:481\u201390.","journal-title":"Psychopharmacology."},{"key":"1324_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. 2013;228:481\u201391.","journal-title":"Exp Brain Res."},{"key":"1324_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.neuropharm.2012.06.007","volume":"64","author":"G Zhang","year":"2013","unstructured":"Zhang G, \u00c1sgeirsd\u00f3ttir HN, Cohen SJ, Munchow AH, Barrera MP, Stackman RW. Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL\/6J mice. Neuropharmacology. 2013;64:403\u201313.","journal-title":"Neuropharmacology."},{"key":"1324_CR36","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1021\/acschemneuro.8b00134","volume":"9","author":"L Cameron","year":"2018","unstructured":"Cameron L, Benson CJ, Dunlap LE, Olson DE. Effects of N,N-dimethyltryptamine on rat behaviors relevant to anxiety and depression. ACS Chem Neurosci. 2018;9:1582\u201390.","journal-title":"ACS Chem Neurosci."},{"key":"1324_CR37","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1021\/acschemneuro.8b00692","volume":"10","author":"L Cameron","year":"2019","unstructured":"Cameron L, Benson CJ, DeFelice BC, Fiehn O, Olson DE. Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci. 2019;10:3261\u201370.","journal-title":"ACS Chem Neurosci."},{"key":"1324_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00213-003-1398-x","volume":"167","author":"CA Winstanley","year":"2003","unstructured":"Winstanley CA, Chudasama Y, Dalley JW, Theobald DEH, Glennon JC, Robbins TW. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology. 2003;167:304\u201314.","journal-title":"Psychopharmacology."},{"key":"1324_CR39","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0031-9384(96)00323-X","volume":"60","author":"NA Darmani","year":"1996","unstructured":"Darmani NA, Shaddy J, Gerdes CF. Differential ontogenesis of three DOI-induced behaviors in mice. Physiol Behav. 1996;60:1495\u20131500.","journal-title":"Physiol Behav."},{"key":"1324_CR40","doi-asserted-by":"crossref","unstructured":"Pierre A, Van Schuerbeek A, Allaoui W, Van Laere S, Singewald N, Van Eeckhaut A, et al. Effects of ghrelin receptor activation on forebrain dopamine release, conditioned fear and fear extinction in C57BL\/6J mice. J Neurochem. 8;154:389\u2013403.","DOI":"10.1111\/jnc.14996"},{"key":"1324_CR41","unstructured":"Paxinos G, Franklin KB. Paxinos and Franklin\u2019s the mouse brain in stereotaxic coordinates. Academic Press; 2019."},{"key":"1324_CR42","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1523\/JNEUROSCI.5465-10.2011","volume":"31","author":"D De Bundel","year":"2011","unstructured":"De Bundel D, Schallier A, Loyens E, Fernando R, Miyashita H, Van Liefferinge J, et al. Loss of system xc\u2212 does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J Neurosci. 2011;31:5792\u2013803.","journal-title":"J Neurosci"},{"key":"1324_CR43","doi-asserted-by":"publisher","first-page":"14731","DOI":"10.1073\/pnas.97.26.14731","volume":"97","author":"Z Sarnyai","year":"2000","unstructured":"Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, T\u00f3th M. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin1A receptors. Proc Natl Acad Sci USA. 2000;97:14731\u20136.","journal-title":"Proc Natl Acad Sci USA."},{"key":"1324_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/mp.2016.223","volume":"23","author":"C Zussy","year":"2018","unstructured":"Zussy C, G\u00f3mez-Santacana X, Rovira X, De Bundel D, Ferrazzo S, Bosch D, et al. Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4. Mol Psychiatry. 2018;23:509\u201320.","journal-title":"Mol Psychiatry."},{"key":"1324_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/epi.13943","volume":"59","author":"G Albertini","year":"2018","unstructured":"Albertini G, Walrave L, Demuyser T, Massie A, De, Bundel D, et al. 6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain. Epilepsia. 2018;59:67\u201378.","journal-title":"Epilepsia."},{"key":"1324_CR46","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods."},{"key":"1324_CR47","doi-asserted-by":"crossref","unstructured":"Wheeler A, Henriques R. Standard and super-resolution bioimaging data analysis: a primer. 312. Wiley Online Library; 2017.","DOI":"10.1002\/9781119096948"},{"key":"1324_CR48","doi-asserted-by":"crossref","unstructured":"Maxwell SE, Delaney HD, Kelley K. Designing experiments and analyzing data: a model comparison perspective. Routledge; 2017.","DOI":"10.4324\/9781315642956"},{"key":"1324_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00213-010-1784-0","volume":"209","author":"CE Canal","year":"2010","unstructured":"Canal CE, da Silva UBO, Gresch PJ, Watt EE, Sanders-Bush E, Airey DC. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology. 2010;209:163\u201374.","journal-title":"Psychopharmacology."},{"key":"1324_CR50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fnbeh.2013.00152","volume":"7","author":"D De Bundel","year":"2013","unstructured":"De Bundel D, Gangarossa G, Biever A, Bonnefont X, Valjent E. Cognitive dysfunction, elevated anxiety, and reduced cocaine response in circadian clock-deficient cryptochrome knockout mice. Front Behav Neurosci. 2013;7:152.","journal-title":"Front Behav Neurosci."},{"key":"1324_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15716-9","volume":"11","author":"E Puighermanal","year":"2020","unstructured":"Puighermanal E, Castell L, Esteve-Codina A, Melser S, Kaganovsky K, Zussy C, et al. Functional and molecular heterogeneity of D2R neurons along dorsal-ventral axis in the striatum. Nat Commun. 2020;11:1957.","journal-title":"Nat Commun."},{"key":"1324_CR52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/cne.902960402","volume":"296","author":"E Bullitt","year":"1990","unstructured":"Bullitt E. Expression of C-fos-like protein as a marker for neuronal activity following noxious stimulation in the rat. J Comp Neurol. 1990;296:517\u201330.","journal-title":"J Comp Neurol."},{"key":"1324_CR53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00213-018-5033-2","volume":"236","author":"R Marek","year":"2019","unstructured":"Marek R, Sun Y, Sah P. Neural circuits for a top-down control of fear and extinction. Psychopharmacology. 2019;236:313\u201320.","journal-title":"Psychopharmacology."},{"key":"1324_CR54","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1038\/npp.2015.157","volume":"40","author":"M Bocchio","year":"2015","unstructured":"Bocchio M, Fucsina G, Oikonomidis L, McHugh SB, Bannerman DM, Sharp T, et al. Increased serotonin transporter expression reduces fear and recruitment of parvalbumin interneurons of the amygdala. Neuropsychopharmacology. 2015;40:3015\u201326.","journal-title":"Neuropsychopharmacology."},{"key":"1324_CR55","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/npp.2008.71","volume":"34","author":"X Jiang","year":"2009","unstructured":"Jiang X, Xing G, Yang C, Verma A, Zhang L, Li H. Stress impairs 5-HT2A receptor-mediated serotonergic facilitation of GABA release in juvenile rat basolateral amygdala. Neuropsychopharmacology. 2009;34:410\u201323.","journal-title":"Neuropsychopharmacology."},{"key":"1324_CR56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/026988119801200210","volume":"12","author":"S Ruotsalainen","year":"1998","unstructured":"Ruotsalainen S, MacDonald E, Koivisto E, Stefanski R, Haapalinna A, Riekkinen P, et al. 5 -HT1A Receptor agonist (8-OH-DPAT) and 5-HT2 receptor agonist (DOI) disrupt the non-cognitive performance of rats in a working memory task. J Psychopharmacol. 1998;12:177\u201385.","journal-title":"J Psychopharmacol."},{"key":"1324_CR57","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/BF00179315","volume":"338","author":"S Hjorth","year":"1988","unstructured":"Hjorth S, Magnusson T. The 5-HT 1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5-HT autoreceptors in rat brain in vivo. Naunyn-Schmiedebergs Arch Pharmacol. 1988;338:463\u201371.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol."},{"key":"1324_CR58","doi-asserted-by":"publisher","first-page":"107838","DOI":"10.1016\/j.neuropharm.2019.107838","volume":"183","author":"AU Odland","year":"2021","unstructured":"Odland AU, Jessen L, Kristensen JL, Fitzpatrick CM, Andreasen JT. The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation. Neuropharmacology. 2021;183:107838.","journal-title":"Neuropharmacology."},{"key":"1324_CR59","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbr.2013.01.005","volume":"243","author":"V-M Papakosta","year":"2013","unstructured":"Papakosta V-M, Kalogerakou S, Kontis D, Anyfandi E, Theochari E, Boulougouris V, et al. 5-HT2C receptor involvement in the control of persistence in the Reinforced Spatial Alternation animal model of obsessive\u2013compulsive disorder. Behav Brain Res. 2013;243:176\u201383.","journal-title":"Behav Brain Res."},{"key":"1324_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bbr.2007.07.011","volume":"185","author":"R Hameleers","year":"2007","unstructured":"Hameleers R, Blokland A, Steinbusch HWM, Visser-Vandewalle V, Temel Y. Hypomobility after DOI administration can be reversed by subthalamic nucleus deep brain stimulation. Behav Brain Res. 2007;185:65\u20137.","journal-title":"Behav Brain Res."},{"key":"1324_CR61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s002130050740","volume":"140","author":"K Krebs-Thomson","year":"1998","unstructured":"Krebs-Thomson K, Geyer MA. Evidence for a functional interaction between 5-HT1A and 5-HT2 receptors in rats. Psychopharmacology. 1998;140:69\u201374.","journal-title":"Psychopharmacology."},{"key":"1324_CR62","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/BF02244617","volume":"100","author":"LL Wing","year":"1990","unstructured":"Wing LL, Tapson GS, Geyer MA. 5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology. 1990;100:417\u201325.","journal-title":"Psychopharmacology."},{"key":"1324_CR63","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF02316866","volume":"105","author":"SM Mittman","year":"1991","unstructured":"Mittman SM, Geyer MA. Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol. Psychopharmacology. 1991;105:69\u201376.","journal-title":"Psychopharmacology."},{"key":"1324_CR64","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/npp.2009.29","volume":"34","author":"AL Halberstadt","year":"2009","unstructured":"Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA, et al. 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology. 2009;34:1958\u201367.","journal-title":"Neuropsychopharmacology."},{"key":"1324_CR65","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/0024-3205(95)02242-9","volume":"57","author":"ES Onaivi","year":"1995","unstructured":"Onaivi ES, Bishop-Robinson C, Darmani NA, Sanders-Bush E. Behavioral effects of (\u00b1)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, (DOI) in the elevated plus-maze test. Life Sci. 1995;57:2455\u201366.","journal-title":"Life Sci"},{"key":"1324_CR66","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0166-4328(03)00179-7","volume":"147","author":"B\u00c1 Nic Dhonnchadha","year":"2003","unstructured":"Nic Dhonnchadha B\u00c1, Hasco\u00ebt M, Jolliet P, Bourin M. Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behav Brain Res. 2003;147:175\u201384.","journal-title":"Behav Brain Res."},{"key":"1324_CR67","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bbr.2005.07.013","volume":"166","author":"N Ripoll","year":"2006","unstructured":"Ripoll N, Hasco\u00ebt M, Bourin M. Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice. Behav Brain Res. 2006;166:131\u20139.","journal-title":"Behav Brain Res."},{"key":"1324_CR68","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0091-3057(93)90305-D","volume":"44","author":"IP Lapin","year":"1993","unstructured":"Lapin IP. Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol. Pharm Biochem Behav. 1993;44:241\u20133.","journal-title":"Pharm Biochem Behav."},{"key":"1324_CR69","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0091-3057(98)00191-9","volume":"62","author":"HQ Lin","year":"1999","unstructured":"Lin HQ, Burden PM, Christie MJ, Johnston GA. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharm Biochem Behav. 1999;62:403\u20138.","journal-title":"Pharm Biochem Behav."},{"key":"1324_CR70","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1211\/jpp.61.04.0012","volume":"61","author":"G Biala","year":"2009","unstructured":"Biala G, Kruk M. Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice. J Pharm Pharmacol. 2009;61:493\u2013502.","journal-title":"J Pharm Pharmacol."},{"key":"1324_CR71","doi-asserted-by":"publisher","first-page":"R868","DOI":"10.1016\/j.cub.2007.08.005","volume":"17","author":"J LeDoux","year":"2007","unstructured":"LeDoux J. The amygdala. Curr Biol. 2007;17:R868\u201374.","journal-title":"Curr Biol."},{"key":"1324_CR72","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0169-328X(99)00195-3","volume":"71","author":"M Ma\u0107kowiak","year":"1999","unstructured":"Ma\u0107kowiak M, Chocyk A, Fija\u0142 K, Czyrak A, Wedzony K. c-Fos proteins, induced by the serotonin receptor agonist DOI, are not expressed in 5-HT2A positive cortical neurons. Brain Res Mol Brain Res. 1999;71:358\u201363.","journal-title":"Brain Res Mol Brain Res."},{"key":"1324_CR73","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ebiom.2016.08.049","volume":"11","author":"DA Martin","year":"2016","unstructured":"Martin DA, Nichols CD. Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain. EBioMedicine. 2016;11:262\u201377.","journal-title":"EBioMedicine."},{"key":"1324_CR74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bbr.2008.08.027","volume":"197","author":"V de Paula Soares","year":"2009","unstructured":"de Paula Soares V, Zangrossi H. Stimulation of 5-HT1A or 5-HT2A receptors in the ventrolateral periaqueductal gray causes anxiolytic-, but not panicolytic-like effect in rats. Behav Brain. 2009;197:178\u201385.","journal-title":"Behav Brain."},{"key":"1324_CR75","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.bbr.2009.06.006","volume":"204","author":"B Petit-Demouli\u00e8re","year":"2009","unstructured":"Petit-Demouli\u00e8re B, Mass\u00e9 F, Cogrel N, Hasco\u00ebt M, Bourin M. Brain structures implicated in the four-plate test in na\u00efve and experienced Swiss mice using injection of diazepam and the 5-HT2A agonist DOI. Behav Brain Res. 2009;204:200\u20135.","journal-title":"Behav Brain Res."},{"key":"1324_CR76","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.euroneuro.2020.08.006","volume":"39","author":"M Hessel","year":"2020","unstructured":"Hessel M, Pape H-C, Seidenbecher T. Stimulation of 5-HT receptors in anterodorsal BNST guides fear to predictable and unpredictable threat. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2020;39:56\u201369.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol."},{"key":"1324_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2014","unstructured":"Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2014;29:57\u201368.","journal-title":"J Psychopharmacol"},{"key":"1324_CR78","doi-asserted-by":"publisher","first-page":"112749","DOI":"10.1016\/j.psychres.2020.112749","volume":"284","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res. 2020;284:112749.","journal-title":"Psychiatry Res."},{"key":"1324_CR79","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165\u201380.","journal-title":"J Psychopharmacol."},{"key":"1324_CR80","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol."},{"key":"1324_CR81","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jad.2019.07.076","volume":"258","author":"S Muttoni","year":"2019","unstructured":"Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: a systematic review. J Affect Disord. 2019;258:11\u201324.","journal-title":"J Affect Disord."},{"key":"1324_CR82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nicl.2015.08.009","volume":"11","author":"R Kraehenmann","year":"2016","unstructured":"Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage Clin. 2016;11:53\u201360.","journal-title":"NeuroImage Clin."},{"key":"1324_CR83","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1038\/npp.2016.82","volume":"41","author":"PC Dolder","year":"2016","unstructured":"Dolder PC, Schmid Y, M\u00fcller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41:2638\u201346.","journal-title":"Neuropsychopharmacology."},{"key":"1324_CR84","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/sj.npp.1300079","volume":"28","author":"VB Risbrough","year":"2003","unstructured":"Risbrough VB, Brodkin JD, Geyer MA. GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology. 2003;28:654\u201363.","journal-title":"Neuropsychopharmacology."},{"key":"1324_CR85","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00213-018-5124-0","volume":"236","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Bijlsma EY, ter Heegde F, Verdouw MP, Garssen J, Newman-Tancredi A, et al. Activation of somatodendritic 5-HT 1A autoreceptors reduces the acquisition and expression of cued fear in the rat fear-potentiated startle test. Psychopharmacology. 2019;236:1171\u201385.","journal-title":"Psychopharmacology."},{"key":"1324_CR86","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1017\/S1461145713000473","volume":"16","author":"C-C Wang","year":"2013","unstructured":"Wang C-C, Lin H-C, Chan Y-H, Gean P-W, Yang YK, Chen PS. 5-HT1A-receptor agonist modified amygdala activity and amygdala-associated social behavior in a valproate-induced rat autism model. Int J Neuropsychopharmacol. 2013;16:2027\u201339.","journal-title":"Int J Neuropsychopharmacol."},{"key":"1324_CR87","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/syn.20657","volume":"63","author":"H Koseki","year":"2009","unstructured":"Koseki H, Matsumoto M, Togashi H, Miura Y, Fukushima K, Yoshioka M. Alteration of synaptic transmission in the hippocampal-mPFC pathway during extinction trials of context-dependent fear memory in juvenile rat stress models. Synapse. 2009;63:805\u201313.","journal-title":"Synapse."},{"key":"1324_CR88","doi-asserted-by":"publisher","first-page":"109836","DOI":"10.1016\/j.celrep.2021.109836","volume":"37","author":"M de la Fuente Revenga","year":"2021","unstructured":"de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37:109836.","journal-title":"Cell Rep."},{"key":"1324_CR89","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF02245610","volume":"124","author":"RA Padich","year":"1996","unstructured":"Padich RA, McCloskey TC, Kehne JH. 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT 2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology. 1996;124:107\u201316.","journal-title":"Psychopharmacology."},{"key":"1324_CR90","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1017\/S1461145710001215","volume":"14","author":"MJ Orejarena","year":"2011","unstructured":"Orejarena MJ, Lanfumey L, Maldonado R, Robledo P. Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour. Int J Neuropsychopharmacol. 2011;14:927\u201340.","journal-title":"Int J Neuropsychopharmacol."},{"key":"1324_CR91","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/0893-133X(95)00160-F","volume":"15","author":"JH Kehne","year":"1996","unstructured":"Kehne JH, Ketteler HJ, McCloskey TC, Sullivan CK, Dudley MW, Schmidt CJ. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology. 1996;15:116\u201324.","journal-title":"Neuropsychopharmacology."},{"key":"1324_CR92","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-004-2030-4","volume":"178","author":"DV Herin","year":"2005","unstructured":"Herin DV, Liu S, Ullrich T, Rice KC, Cunningham KA. Role of the serotonin 5-HT 2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology. 2005;178:505\u201313.","journal-title":"Psychopharmacology."},{"key":"1324_CR93","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/npp.2017.80","volume":"42","author":"EG Pitts","year":"2017","unstructured":"Pitts EG, Minerva AR, Chandler EB, Kohn JN, Logun MT, Sulima A, et al. 3,4-Methylenedioxymethamphetamine increases affiliative behaviors in squirrel monkeys in a serotonin 2A receptor-dependent manner. Neuropsychopharmacology. 2017;42:1962\u201371.","journal-title":"Neuropsychopharmacology."}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01324-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01324-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01324-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:04:37Z","timestamp":1652871877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01324-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":93,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1038\/s41386-022-01324-2","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}